Pepgen Inc. (PEPG) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors To Seek Compensation For Alleged Wrongdoings

2024-08-01 04:17:44

(MENAFN- GlobeNewsWire - Nasdaq) NEW YORK, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of PepGen Inc. (“PepGen” or“the Company”) (NASDAQ: PEPG). Investors who purchased PepGen securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/PEPG .

Investigation Details

PepGen released data from its ongoing Phase 2 trial of its drug candidate PGN-EDO51 on July 30, 2024. Following this news, PepGen stock dropped over 45% during intraday trading on the next day.

What's Next?

If you are aware of any facts relating to this investigation or purchased PepGen securities, you can assist this investigation by visiting the firm's site: . You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 332-239-2660.

There is No Cost to You

We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.

Why Bronstein, Gewirtz & Grossman

Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.

Attorney advertising. Prior results do not guarantee similar outcomes.

Contact

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Nathan Miller
332-239-2660 | ...

MENAFN01082024004107003653ID1108508269

Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.